Clinical Trials Logo
  1. Home
  2. Germ Cell Tumors
  3. NCT01873326

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Germ Cell Tumors Clinical Trial

Official title:
Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors

Clinical Trial Summary

The purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT). One combination of drugs, paclitaxel, ifosfamide and cisplatin (TIP), is experimental. The other combination of drugs, bleomycin, etoposide and cisplatin (BEP), is the standard of care treatment for intermediate- and poor-risk germ cell tumors. However, BEP does not cure every patient and therefore newer treatments are needed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01873326
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 2013
Completion date June 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Completed NCT01505569 - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors N/A
Withdrawn NCT03726281 - Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors Phase 2
Completed NCT01743482 - Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors Phase 2
Terminated NCT02689219 - Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Phase 2
Completed NCT00864318 - Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis Phase 2
Completed NCT00187109 - Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy Phase 1/Phase 2
Completed NCT02162732 - Molecular-Guided Therapy for Childhood Cancer N/A
Completed NCT02390843 - Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Phase 1
Completed NCT04283773 - Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Completed NCT00572572 - Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors Phase 3
Completed NCT02161692 - Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors Phase 2
Withdrawn NCT04648826 - Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies Phase 1/Phase 2